» Articles » PMID: 32373211

Marizomib Suppresses Triple-negative Breast Cancer Via Proteasome and Oxidative Phosphorylation Inhibition

Abstract

: Lacking effective targeted therapies, triple-negative breast cancer (TNBCs) is highly aggressive and metastatic disease, and remains clinically challenging breast cancer subtype to treat. Despite the survival dependency on the proteasome pathway genes, FDA-approved proteasome inhibitors induced minimal clinical response in breast cancer patients due to weak proteasome inhibition. Hence, developing effective targeted therapy using potent proteasome inhibitor is required. : We evaluated anti-cancer activity of a potent proteasome inhibitor, marizomib, using breast cancer lines and using 4T1.2 murine syngeneic model, MDA-MB-231 xenografts, and patient-derived tumor xenografts. Global proteome profiling, western blots, and RT-qPCR were used to investigate the mechanism of action for marizomib. Effect of marizomib on lung and brain metastasis was evaluated using syngeneic 4T1BR4 murine TNBC model . : We show that marizomib inhibits multiple proteasome catalytic activities and induces a better anti-tumor response in TNBC cell lines and patient-derived xenografts alone and in combination with the standard-of-care chemotherapy. Mechanistically, we show that marizomib is a dual inhibitor of proteasome and oxidative phosphorylation (OXPHOS) in TNBCs. Marizomib reduces lung and brain metastases by reducing the number of circulating tumor cells and the expression of genes involved in the epithelial-to-mesenchymal transition. We demonstrate that marizomib-induced OXPHOS inhibition upregulates glycolysis to meet the energetic demands of TNBC cells and combined inhibition of glycolysis with marizomib leads to a synergistic anti-cancer activity. : Our data provide a strong rationale for a clinical evaluation of marizomib in primary and metastatic TNBC patients.

Citing Articles

Structural insights into Salinosporamide A mediated inhibition of the human 20S proteasome.

Sulzen H, Fajtova P, ODonoghue A, Boura E, Silhan J bioRxiv. 2025; .

PMID: 39974992 PMC: 11838377. DOI: 10.1101/2025.01.28.635221.


The Spatial Distribution of Brain Metastasis Is Determined by the Heterogeneity of the Brain Microenvironment.

Bao H, Ren P, Liang X, Lai J, Bai Y, Liu Y Hum Brain Mapp. 2024; 45(18):e70103.

PMID: 39720836 PMC: 11669001. DOI: 10.1002/hbm.70103.


CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

Raninga P, Zeng B, Moi D, Trethowan E, Saletta F, Venkat P Oncogene. 2024; .

PMID: 39706891 DOI: 10.1038/s41388-024-03259-y.


Marizomib Promotes Senescence or Long-Term Apoptosis in Melanoma Cancer Cells.

Piskorz W, Kretowski R, Cechowska-Pasko M Molecules. 2024; 29(23).

PMID: 39683813 PMC: 11643135. DOI: 10.3390/molecules29235652.


Tumor energy metabolism: implications for therapeutic targets.

Hu Y, Liu W, Fang W, Dong Y, Zhang H, Luo Q Mol Biomed. 2024; 5(1):63.

PMID: 39609317 PMC: 11604893. DOI: 10.1186/s43556-024-00229-4.


References
1.
Lagadinou E, Sach A, Callahan K, Rossi R, Neering S, Minhajuddin M . BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013; 12(3):329-41. PMC: 3595363. DOI: 10.1016/j.stem.2012.12.013. View

2.
Petrocca F, Altschuler G, Tan S, Mendillo M, Yan H, Jerry D . A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer Cell. 2013; 24(2):182-96. PMC: 3773329. DOI: 10.1016/j.ccr.2013.07.008. View

3.
Manton C, Johnson B, Singh M, Bailey C, Bouchier-Hayes L, Chandra J . Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo. Sci Rep. 2016; 6:18953. PMC: 4726202. DOI: 10.1038/srep18953. View

4.
Sancho P, Burgos-Ramos E, Tavera A, Bou Kheir T, Jagust P, Schoenhals M . MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells. Cell Metab. 2015; 22(4):590-605. DOI: 10.1016/j.cmet.2015.08.015. View

5.
Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G . Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 2006; 12(19):5615-21. DOI: 10.1158/1078-0432.CCR-06-0169. View